Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (FRA:FDY) Gross Profit Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co had a gross margin of 89.40% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Gross Profit Related Terms
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Gross Profit Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Gross Profit Chart
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Annual Data
For the Drug Manufacturers - Specialty & Generic subindustry, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Gross Profit vs Drug Manufacturers Industry
Gross Profit for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €32.04 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (FRA:FDY) has a Gross Profit of €32.04 Mil as of Dec. 2025. Gross Profit equals net sales less total cost of goods sold. View historical data on Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co and its competitors.
Is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Gross Profit too high?
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's current Gross Profit is €32.04 Mil. Overall, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co has a GF Score™ of 69/100, reflecting its overall financial health beyond just this single metric.
How does Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Gross Profit compare to ZTS?
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Gross Profit of €32.04 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Profit for a Drug Manufacturers company?
A good Gross Profit depends on the Drug Manufacturers industry context. However, Gross Profit should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Profit mean?
A high Gross Profit can signal that a stock is expensive relative to its fundamentals. Gross Profit equals net sales less total cost of goods sold. View historical data on Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co and its competitors. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's current Gross Profit is €32.04 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co stock overvalued right now?
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (FRA:FDY) has a current Gross Profit of €32.04 Mil. The stock's GF Value™ is €0.24, compared to a current price of €0.28 — trading 15% above its estimated fair value. The current Gross Profit is €32.04 Mil. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Profit calculated?
Gross Profit is calculated from a company's financial statements. For Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (FRA:FDY), the current Gross Profit is €32.04 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (FRA:FDY) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co stock appears to be overvalued.
The current stock price of €0.28 is trading 15% above its estimated GF Value™ of €0.24.
Key valuation signals for FRA:FDY:
Gross Profit: €32.04 Mil
GF Value™: €0.24 vs. price of €0.28 (15% above fair value)
No single metric tells the full story. See the FRA:FDY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd is engaged in the research, development, manufacturing, and sale of biopharmaceutical products. Its product portfolio includes ALA (Aminolevulinic acid Hydrochloride); FuMeiDa and Libord. The company has launched it's four types of photodynamic drugs in China market, namely hematoporphyrin, aminolevulinic acid hydrochloride, Verteporfin and Hemoporfin. Geographically, it derives revenue from Mainland China.
69GF Score
Get the complete analysis for FRA:FDY
Gross Profit is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:FDY has been successfully added to your 
